Abstract: The invention relates to labelling agents containing a compound with two labelled molecules and a vinyl sulphone group. The invention also relates to the compounds, the method for obtaining these and the uses thereof in the marking of biomolecules and, more specifically, proteins.

Abstract: The present invention relates to a process for producing water-absorbent polymer particles by polymerizing droplets of a monomer solution in a surrounding heated gas phase and flowing the gas cocurrent through the polymerization chamber, wherein the temperature of the gas leaving the polymerization chamber is 130° C. or less, the gas velocity inside the polymerization chamber is at least 0.5 m/s, and the droplets are generated by using a droplet plate having a multitude of bores.

Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, R1, R2, R3, R4, R5, Ra and Rb are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with the P2X7 purinergic receptor.

Abstract: Mixtures comprising (A) at least one hydraulic or latently hydraulic binder, (B) at least one copolymer obtainable by reacting (?1) at least one ethylenically unsaturated comonomer having at least one functional group selected from COOH groups, sulfonic acid groups, nitrile groups, hydroxyalkyl groups and amino groups, or (?2) at least one (co)polymer of at least one ethylenically unsaturated comonomer having at least one functional group selected from COOH groups, sulfonic acid groups, nitrile groups, hydroxyalkyl groups and amino groups, with (?) at least one oligomeric or polymeric compound obtainable by reacting (a) at least one ethylenically unsaturated di- or polycarboxylic acid or anhydride or ester thereof with (b) at least one at least trifunctional alcohol and (c) at least one compound of the general formula I in which the variables are each defined as follows: R1 is selected from C1-C4-alkyl and hydrogen, A is the same or different and is selected from C2-C6-alkylene, n is in the range f

Abstract: A process for producing surface postcrosslinked water-absorbing polymer particles, wherein the water-absorbing polymer particles are coated, before, during or after the surface postcrosslinking, with at least one basic salt of a trivalent metal cation and a monovalent carboxylic acid anion.

Abstract: Compounds of the formula I: wherein m, n, Ar, R1 and R2 are as defined herein. Methods of making the compounds and using the compounds are disclosed.

Abstract: Compounds of the formula I: wherein m, n, p, X, Ar, R1, R2, R3, R4 and R5 are as defined herein. Methods of making the compounds and using the compounds for treatment of 5-HT6 receptor-mediated diseases are disclosed.

Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, R1, R2, R3, R4, R5 and Ra are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with the P2X7 purinergic receptor.

Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, R1, R2, R3, R4 and R5 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with the P2X7 purinergic receptor.

Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, R1, R2, R3, R4 and R5 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with the P2X7 purinergic receptor.

Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, p, q, R1, R2, R3, R4, R5 and R6 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with the P2X7 purinergic receptor.

Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, R1, R2, R3, R4, R5 and Ra are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with the P2X7 purinergic receptor.

Abstract: The present invention relates to a coin return process applicable in coin returns in which at least two types i of coins of different values coexist in a single storage area. The process has the steps of: obtaining a total value to be returned; assigning different initial weights Weighti0 to each of the at least two types of coin, i<=2; identifying the coin to be extracted or recovered by the return prior to its extraction or recovery; Weightsi? is equal to a pre-established value, in which case the coin is extracted. Then, modifying, after the identification of, Weighti? the coin to be extracted or recovered by the return, the weight assigned to the identified coin, where the Weighti? being the modified weight; and, checking if the modified weight, Weighti? is equal to a pre-established value, in which case the coin is extracted.

Abstract: Compounds of the formula I: wherein m, n, Ar, R1 and R2 are as defined herein. Methods of making the compounds and using the compounds are disclosed.

Abstract: Compounds effective as IP receptor modulators, particularly IP receptor antagonists, that are of the formula I: wherein A, R1, R2, R3 and R4 are as defined in the specification; and individual isomers, racemic or non-racemic mixtures of isomers, and pharmaceutically acceptable salts or solvates thereof. Also disclosed are pharmaceutical compositions containing such compounds and methods for their use as therapeutic agents.

Abstract: Compounds represented by Formula I: which are useful as are alpha-1A/B adrenoceptor antagonists, to methods of treating conditions associated with the activity of alpha-1A/B adrenoceptors, and to methods of making said compounds, wherein Ar, Z, R, R?, R5 and R10 are as defined herein.

Abstract: This invention relates to IP receptor antagonists selected from the group of compounds represented by Formula I: where: R1 is a group represented by formula (A), (B) or (C); and other substituents as defined in the specification, and their pharmaceutically acceptable salts or crystal forms thereof; and pharmaceutical compositions containing them; and methods for their use as therapeutic agents.

Abstract: Compounds effective as IP receptor modulators, particularly IP receptor antagonists, that are of the formula I: wherein A, R1, R2, R3 and R4 are as defined in the specification; and individual isomers, racemic or non-racemic mixtures of isomers, and pharmaceutically acceptable salts or solvates thereof. Also disclosed are pharmaceutical compositions containing such compounds and methods for their use as therapeutic agents.

Abstract: This invention relates to compounds which are generally IP receptor antagonists and which are represented by Formula I: wherein G1 is selected from the group consisting of a, b1 and b2, and A and G2 are as defined in the specification; or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and methods of preparation thereof.

Abstract: Compounds effective as IP receptor modulators, particularly IP receptor antagonists, that are of the formula I: 1